FLt3 ligand increases dendritic cell count in prostate cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1432-1433, 2004-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Flt3 Ligand Bioactivity and Pharmacology in Neoplasia

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 4, Iss. 2, 2004-06 ,pp. : 149-156

Bentham Science Publishers

Access to resources Recommend Favorite

ADT in prostate cancer increases diabetes and fractures, but not MI

Reactions Weekly, Vol. 1, Iss. 1261, 2009-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Leuprorelin increases bodyfat in men with prostate cancer

Inpharma, Vol. 1, Iss. 1330, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Dendritic cell-based approaches to cancer immunotherapy

By Morse M.A. Lyerly H.K.

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 10, 1998-10 ,pp. : 1617-1627

Informa Healthcare

Access to resources Recommend Favorite

Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines

Current Cancer Drug Targets, Vol. 16, Iss. 4, 2016-04 ,pp. : 373-385

Bentham Science Publishers

Access to resources Recommend Favorite